A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy.
about
Octreotide for inoperable malignant bowel obstructionChemotherapy and radiotherapy for inoperable advanced pancreatic cancerChemotherapy and radiotherapy for inoperable advanced pancreatic cancerSupportive care for patients with gastrointestinal cancerOctreotide for inoperable malignant bowel obstructionPlacebo effects in oncology.Biotherapeutic approaches to pancreatic cancer.Promoter hypermethylation-related reduced somatostatin production promotes uncontrolled cell proliferation in colorectal cancer.Microencapsulated octreotide pamoate in advanced gastrointestinal and pancreatic cancer: a phase I study.Somatostatin receptor subtype mRNA expression in human colorectal cancer and normal colonic mucosae.Regulatory effect and mechanism of gastrin and its antagonists on colorectal carcinomaPeptide receptor targeting in cancer: the somatostatin paradigm.Effect of octreotide on cell-cycle kinetics and serum carcinoembryonic antigen level in hepatic metastases of colonic adenocarcinoma.A review of the use of somatostatin analogs in oncologyMolecular signatures of mu opioid receptor and somatostatin receptor 2 in pancreatic cancer.Pharmacological treatment of bowel obstruction in cancer patients.Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors.Octreotide prescribing patterns in the palliation of symptomatic inoperable malignant bowel obstruction patients at a single US academic hospital.Implementation of supportive care and best supportive care interventions in clinical trials enrolling patients with cancer†.Antineoplastic effects of octreotide on human gallbladder cancer cells in vitro.Lanreotide-induced modulation of 5-fluorouracil or mitomycin C cytotoxicity in human colon cancer cell lines: a preclinical study.
P2860
Q24239846-7D25F06B-51D9-49F9-B174-0879B72BFAB2Q24240739-2DF7CEFE-981D-4CB8-8EA6-2C39A58123C6Q24245085-67CB788D-8033-4F54-A0BD-76070DAA68C4Q24246675-B515C044-7733-4FF5-A898-68D518A318EDQ26472136-34C0CCAF-0A28-4ACF-8AD4-554922E89DD5Q35037527-A081D974-C910-46B8-8933-ABD945A329FFQ35093628-E0E24B9C-1032-4F8C-B812-34571B63C882Q35130509-FDE1F0CE-17D4-457D-8FEE-757F78E68821Q36114875-3B3E2075-DC5A-40CB-8852-7F802BB1156FQ36116318-B778887F-E783-4D0F-918D-FA025ECAABF8Q36397112-64A341C6-3BA4-452F-8BEA-31DE2FDAD2BEQ36638046-DAE46F97-6EF6-4133-8F76-45E430B78CF3Q36712564-1837965D-632B-40C4-B672-3B2B2F96BABDQ36833161-1D7C9FF3-9492-41DA-BFE3-9C6A45AE7774Q37573308-E984018D-1B6F-48AE-9BE0-8BE35AA42D28Q37895712-9FC8031F-E06C-4B6D-B379-F608DB0D6FC3Q37898112-1DA6D4EB-AB48-430C-BD2C-050B85B926DCQ38111630-396B3FA0-65B5-4C7D-B830-76E1EAE5FEC4Q38447986-D24B54CB-A0D1-411E-9BB0-9FC3EA0D5BA5Q40571857-895312C8-58CF-4BCD-9C35-AEB528A5BD4CQ40835915-18E24661-7598-4C67-9506-7B7C9B30026C
P2860
A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
A randomised trial of octreoti ...... ts refractory to chemotherapy.
@ast
A randomised trial of octreoti ...... ts refractory to chemotherapy.
@en
type
label
A randomised trial of octreoti ...... ts refractory to chemotherapy.
@ast
A randomised trial of octreoti ...... ts refractory to chemotherapy.
@en
prefLabel
A randomised trial of octreoti ...... ts refractory to chemotherapy.
@ast
A randomised trial of octreoti ...... ts refractory to chemotherapy.
@en
P2093
P2860
P356
P1476
A randomised trial of octreoti ...... ts refractory to chemotherapy.
@en
P2093
Catalano G
Del Ferro E
P2860
P2888
P304
P356
10.1038/BJC.1995.19
P407
P577
1995-01-01T00:00:00Z